全球循环系统药物市场规模、份额、趋势和成长分析报告（2026-2034）

预计心血管药物市场将从 2025 年的 1,382.1 亿美元成长到 2034 年的 1,953.6 亿美元，2026 年至 2034 年的复合年增长率为 3.92%。

随着心血管疾病在全球日益普遍，全球心血管药物市场正显着成长。心血管药物用于治疗高血压、心臟衰竭、心律不整和冠状动脉疾病等。这些药物有助于调节血压、改善心臟功能并降低严重併发症的风险。

多种因素正在推动心血管药物市场的成长。人口老化、久坐的生活方式和不健康的饮食习惯导致心血管疾病发生率上升。药物研发的进步正推动着治疗心臟病的有效药物的开发。

随着医疗保健系统将重点转向预防和长期治疗策略，心血管药物市场预计将持续成长。创新药物疗法和个人化医疗的持续研究将改善患者的治疗效果。随着人们对心臟健康的日益关注和医疗保健投资的不断增加，对心血管药物的需求预计将保持强劲。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球循环系统药物市场：依药物类别划分

• 市场分析、洞察与预测
• 抗高血压药物
• 血脂异常症药物
• 抗凝血物
• 抗心律不整药物
• 其他药物分类

第五章 全球循环系统药物市场：依适应症划分

• 市场分析、洞察与预测
• 高血压
• 高血脂症
• 冠状动脉疾病
• 心律不整
• 其他迹象

第六章 全球循环系统药物市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 肠外
• 其他给药途径

第七章 全球循环系统药物市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 网路药房
• 零售药房
• 其他分销管道

第八章 全球循环系统药物市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Amgen
  • AstraZeneca
  • Baxter
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • Lupin
  • Merck
  • Novartis
  • Pfizer

The Cardiovascular Drugs Market size is expected to reach USD 195.36 Billion in 2034 from USD 138.21 Billion (2025) growing at a CAGR of 3.92% during 2026-2034.

The global cardiovascular drugs market has grown significantly due to the increasing prevalence of heart-related diseases worldwide. Cardiovascular drugs are used to treat conditions such as hypertension, heart failure, arrhythmias, and coronary artery disease. These medications help regulate blood pressure, improve heart function, and reduce the risk of serious complications.

Several factors are driving the growth of the cardiovascular drugs market. Aging populations, sedentary lifestyles, and unhealthy dietary habits have contributed to a higher incidence of cardiovascular diseases. Advances in pharmaceutical research have led to the development of more effective medications for managing heart conditions.

In the future, the cardiovascular drugs market is expected to continue growing as healthcare systems focus on preventive and long-term treatment strategies. Ongoing research into innovative drug therapies and personalized medicine will improve patient outcomes. With rising awareness of heart health and increasing healthcare investments, demand for cardiovascular drugs will remain strong.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Antihypertensives
• Antihyperlipidemic
• Anticoagulants
• Antiarrhythmics
• Other Drug Classes

By Indication

• Hypertension
• Hyperlipidemia
• Coronary Artery Disease
• Arrhythmia
• Other Indications

By Route of Administration

• Oral
• Parenteral
• Other Routes of Administration

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Other Distribution Channels

COMPANIES PROFILED

• Amgen, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, BristolMyers Squibb, Gilead Sciences, Johnson Johnson, Lupin, Merck, Novartis, Pfizer
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Antihypertensives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antihyperlipidemic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Anticoagulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Antiarrhythmics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Hypertension Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hyperlipidemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Coronary Artery Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Arrhythmia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Routes of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Distribution Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Indication
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Indication
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Indication
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Indication
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Indication
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CARDIOVASCULAR DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Amgen
  • 10.2.2 AstraZeneca
  • 10.2.3 Baxter
  • 10.2.4 Bayer
  • 10.2.5 Boehringer Ingelheim
  • 10.2.6 Bristol-Myers Squibb
  • 10.2.7 Gilead Sciences
  • 10.2.8 Johnson & Johnson
  • 10.2.9 Lupin
  • 10.2.10 Merck
  • 10.2.11 Novartis
  • 10.2.12 Pfizer